Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2015 Mar;28(1):14-21.
doi: 10.1016/j.beha.2014.11.003. Epub 2014 Nov 11.

Immunophenotyping for diagnosis and prognosis in MDS: ready for general application?

Eline M P Cremers  1 , Canan Alhan  1 , Theresia M Westers  1 , Gert J Ossenkoppele  1 , Arjan A van de Loosdrecht  2
Affiliations
Review

Immunophenotyping for diagnosis and prognosis in MDS: ready for general application?

Eline M P Cremers et al. Best Pract Res Clin Haematol. 2015 Mar.

Abstract

Myelodysplastic syndromes is a heterogeneous group of bone marrow diseases ranging from low risk to high risk subtypes that may rapidly evolve to acute myeloid leukemia. Flow cytometry (FCM) is added as a recommended tool for diagnostic purposes in MDS. In recent studies FCM has also shown applicable to predict prognosis and treatment response. This review summarizes current data about the diagnostic, prognostic and therapeutic value of FCM in MDS. The high sensitivity of FCM in the detection of dysplasia in myelo-/monocytic and erythroid cell lineages makes it a valuable tool to distinguish possible clonal causes of cytopenia(s) from non-clonal causes, and to detect multi-lineage dysplasia in addition to cytomorphology. The utility of FCM in prediction of treatment response is promising. Therefore, FCM is an essential tool in standard diagnostic strategies in case of suspected MDS, and ready for general application.

Keywords: MDS; diagnosis; flow cytometry; prognosis; treatment response.

PubMed Disclaimer

MeSH terms